Estrogen Receptor Beta 2 antibody | 57/3
Immunoexpression of ERs in endometrial cancers.
Image caption:
Tissues were classified as well (A-D), moderately (E-H) or poorly (J-M) differentiated; main panels show closely adjacent sections from three cancer blocks to allow direct comparisons. All proteins were immunolocalised to cell nuclei (see higher power inserts in panels e, f, c and d respectively). In the well and moderately differentiated cancers expression was most intense in epithelial cell layers (arrowheads, panel A and inserts). Note that ERα was low/absent in poor grade cancers (J) but immunoexpression of ERβ1, 2, 5 was readily detected (K. L, M). Inserts in panels K, L, and M show negative controls for ERβ1, ERβ2 and ERβ5 antibodies respectively generated using primary antibodies pre-absorbed with specific peptides used for immunisation. Asterisks (*) label the stromal compartment that was well defined in the well differentiated cancers.
From: Collins F, MacPherson S, Brown P, Bombail V, Williams AR, Anderson RA, Jabbour HN, Saunders PT.
Expression of oestrogen receptors, ERalpha, ERbeta, and ERbeta variants, in endometrial cancers and evidence that prostaglandin F may play a role in regulating expression of ERalpha.
BMC Cancer. 2009 Sep 16;9:330.
This image is from an open access article distributed under the terms of the Creative Commons Attribution License.
Mouse anti Human estrogen receptor β2 used for the detection of ERβ2 expressing cells in tumor tissue by immunohistochemistry in formalin fixed, paraffin embedded tissue sections.
Image caption:
Effect of gender on ERβ1, ERβ2 and ERβ5 expression in D283 Med xenografts. A) Immunostaining for ERβ1 was significantly higher in tumors from females compared to males (**p<0.01); B) and C) Tumor levels of ERβ2 and ERβ5 did not significantly differ between females and males. All results are expressed as the mean ± SEM (n = 6 tumors/group). Representative stained section of tumors from females and males are shown (magnification 40x). IHC, immunohistochemical score.
From: Ciucci A, Meco D, De Stefano I, Travaglia D, Zannoni GF, et al. (2014) Gender Effect in Experimental Models of Human Medulloblastoma: Does the Estrogen Receptor β Signaling Play a Role? PLoS ONE 9(7): e101623.
This image is from an open access article distributed under the terms of the Creative Commons Attribution License.
Mouse anti Human estrogen receptor β2 (MCA2279) used for the detection of ERβ2 expressing cells in normal human liver by immunohistochemistry on formalin fixed, paraffin embedded tissue sections.
Image caption:
Staining pattern of the ERβ isoforms in human liver. In order to confirm the specificity of the ERβ antibodies used in the study, we immunostained sections of human healthy liver, showing that ERβ1 and ERβ2 isoforms are not expressed, while specific nuclear ERβ5 immunoreactivity is detected (magnification 20x and 40x). This pattern of ERβ isoforms immunoreactivity is consistent with previous descriptions.
From: Ciucci A, Meco D, De Stefano I, Travaglia D, Zannoni GF, et al. (2014) Gender Effect in Experimental Models of Human Medulloblastoma: Does the Estrogen Receptor β Signaling Play a Role? PLoS ONE 9(7): e101623.
This image is from an open access article distributed under the terms of the Creative Commons Attribution License.
Mouse anti Human Estrogen Receptor beta 2 antibody, clone 57/3 recognizes the estrogen receptor beta 2 isoform, expressed in cell nuclei of a range of human tissues including the ovary, placenta, testis and vas deferens. No cross-reactivity is seen with estrogen receptor beta 1 isoform.
The detection of estrogen (ER) and progesterone (PR) receptors using immunohistochemical staining of formal fixed paraffin embedded (FFPE) tissue, has gradually replaced ligand binding assays (LBA), to become the most common method for the determination of the ER/PR status of breast tumors. Approximately 75% to 80% of breast tumors have estrogen and/or progesterone receptors, and the presence of these receptors helps determine both the patient’s prognosis and the effectiveness of hormonal therapy
The detection of estrogen (ER) and progesterone (PR) receptors using immunohistochemical staining of formal fixed paraffin embedded (FFPE) tissue, has gradually replaced ligand binding assays (LBA), to become the most common method for the determination of the ER/PR status of breast tumors. Approximately 75% to 80% of breast tumors have estrogen and/or progesterone receptors, and the presence of these receptors helps determine both the patient’s prognosis and the effectiveness of hormonal therapy
Product Details
- Target Species
- Human
- Product Form
- Purified IgG - liquid
- Buffer Solution
- Phosphate buffered saline
- Preservative Stabilisers
- 0.09% Sodium Azide (NaN3)
- Immunogen
- Synthetic peptide derived from the C terminus of the human estrogen receptor beta 2 isomer, CGMKMETLLPEATMEQ.
- Approx. Protein Concentrations
- IgG concentration 1.0mg/ml
- Fusion Partners
- Spleen cells from immunized Balb/c mice were fused with cells of the SP2/0 myeloma cell line.
Storage Information
- Storage
- Store at +4oC or at -20oC if preferred.
This product should be stored undiluted.
Storage in frost-free freezers is not recommended. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use. - Shelf Life
- 18 months from date of despatch.
More Information
- UniProt
- Q92731 Related reagents
- Entrez Gene
- ESR2 Related reagents
- Regulatory
- For research purposes only
Applications of Estrogen Receptor Beta 2 antibody
| Application Name | Verified | Min Dilution | Max Dilution |
|---|---|---|---|
| Immunohistology - Paraffin 1 | 1/50 | 1/500 | |
| Western Blotting |
- 1This product requires antigen retrieval using heat treatment prior to staining of paraffin sections.Sodium citrate buffer pH 6.0 is recommended for this purpose. Glycine/ EDTA preparations have also been used with success in some tissues
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using the appropriate negative/positive controls.
- Histology Positive Control Tissue
- Testis
Copyright © 2019 Bio-Rad Antibodies (formerly AbD Serotec)
Secondary Antibodies Available
Product Specific References
References for Estrogen Receptor Beta 2 antibody
-
Saunders, P.T. et al. (2002) ERbeta1 and the ERbeta2 splice variant (ERbetacx/beta2) are expressed in distinct cell populations in the adult human testis.
J Clin Endocrinol Metab. 87 (6): 2706-15. -
Critchley, H.O. et al. (2002) Wild-type estrogen receptor (ERbeta1) and the splice variant (ERbetacx/beta2) are both expressed within the human endometrium throughout the normal menstrual cycle.
J Clin Endocrinol Metab. 87 (11): 5265-73. -
Gaskell, T.L. et al. (2003) Differential expression of two estrogen receptor beta isoforms in the human fetal testis during the second trimester of pregnancy.
J Clin Endocrinol Metab. 88 (1): 424-32. -
Scobie, G.A. et al. (2002) Human oestrogen receptors: differential expression of ER alpha and beta and the identification of ER beta variants.
Steroids. 67 (12): 985-92. -
Wong, N.A. et al. (2005) ERbeta isoform expression in colorectal carcinoma: an in vivo and in vitro study of clinicopathological and molecular correlates.
J Pathol. 207 (1): 53-60. -
Collins, F. et al. (2009) Expression of oestrogen receptors, ERalpha, ERbeta, and ERbeta variants, in endometrial cancers and evidence that prostaglandin F may play a role in regulating expression of ERalpha.
BMC Cancer. 9: 330. -
Carpino, A. et al. (2007) Detection of aromatase and estrogen receptors (ERalpha, ERbeta1, ERbeta2) in human Leydig cell tumor.
Eur J Endocrinol. 157 (2): 239-44. -
Miller, W.R. et al. (2006) Oestrogen receptor beta and neoadjuvant therapy with tamoxifen: prediction of response and effects of treatment.
Br J Cancer. 94 (9): 1333-8. -
Rago, V. et al. (2009) Identification of ERbeta1 and ERbeta2 in human seminoma, in embryonal carcinoma and in their adjacent intratubular germ cell neoplasia.
Reprod Biol Endocrinol. 7: 56. -
Skliris, G.P. et al. (2006) Expression of oestrogen receptor-beta in oestrogen receptor-alpha negative human breast tumours.
Br J Cancer. 95 (5): 616-26. -
Critchley, H.O. et al. (2002) Wild-type estrogen receptor (ERbeta1) and the splice variant (ERbetacx/beta2) are both expressed within the human endometrium throughout the normal menstrual cycle.
J Clin Endocrinol Metab. 87 (11): 5265-73. -
Ciucci, A. et al. (2014) Gender effect in experimental models of human medulloblastoma: does the estrogen receptor β signaling play a role?
PLoS One. 9 (7): e101623. -
Ciucci, A. et al. (2015) Mitochondrial estrogen receptor β2 drives antiapoptotic pathways in advanced serous ovarian cancer.
Hum Pathol. 46 (8): 1138-46. -
Zannoni, G.F. et al. (2016) Sexual dimorphism in medulloblastoma features.
Histopathology. 68 (4): 541-8. -
Buttarelli, M. et al. (2017) Hormone receptor expression profile of low-grade serous ovarian cancers.
Gynecol Oncol. Feb 20. pii: S0090-8258(17)30150-6. [Epub ahead of print] -
Ciucci, A. et al. (2018) Estrogen receptor β: Potential target for therapy in adult granulosa cell tumors?
Gynecol Oncol. 150 (1): 158-65.
